4/8/13. Pre-test Audience Response. Prostate Cancer Screening and Treatment of Prostate Cancer: The 2013 Perspective
|
|
- Edwin Conrad George
- 7 years ago
- Views:
Transcription
1 Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light of the new USPSTF D recommendation, I plan to reduce / stop PSA screening in my practice. 3. The USPSTF D recommendation is not strongly evidence-based, and will not change my practice. Nicholas A. Daniels, MD, MPH Department of Medicine Declaration of full disclosure: No conflict of interest 4. I am unaware of the USPSTF D recommendation. 2 Prostate Cancer 2012 Urologic cancer: Cases and Deaths American Cancer Society Siegel et al. CA Cancer J Clin 2012; 62:
2 The Good News: Prostate Cancer Screening Controversy 40% drop in ageadjusted prostate cancer mortality since early 1990s Siegel et al. CA Cancer J Clin 2012; 62:10 Moyer et al. Ann Intern Med, epub Other Prostate Cancer Screening Recommendations Prostate cancer is heterogeneous American Cancer Society Informed decision making for prostate cancer screening at age 50 years American Urological Association Recommends annual screening with both PSA and DRE starting at age 40 if life expectancy > 10 years American College of Physicians Informed decision making and discussion of potential benefits and harms of PSA screening with men >50 years Esserman et al. JAMA 2009; 302:
3 The Changing Face of Prostate Cancer PLCO Prostate, Lung, Colorectal, & Ovarian Cancer Screening Trial Cooperberg et al. J Urol 2007; 178:S14 Andriole et al. NEJM 2009; 360: PLCO 76,693 men aged randomly assigned to annual PSA screening for 6 years vs. usual care at 10 U.S. centers Any prior screening allowed; no more than 1 PSA within past 3 years 44.1% of control group had 1 PSA in past 3 years; 53.9% had 1 DRE PSA >4.0 ng/ml considered abnormal Andriole et al. NEJM 2009; 360:1310 PLCO Screening compliance 85% in screening arm Rate of screening in control arm 40% in first year, 52% in sixth year Rate of biopsy among those with PSA >4 fell from 40% in first year to 30% by third year At 7 years, prostate cancer diagnosed in 2820 screening pts and 2322 controls, RR 1.22 ( ) 96.0% vs 94.3% of screened vs control tumors were stage I-II; 32% vs 39% were GS 7 At 7 years, 50 cancer-specific deaths in screening group, 44 in control group, RR 1.13 ( ) Andriole et al. NEJM 2009; 360:
4 PLCO: Level of Contamination PLCO: the contamination problem Data from surveys of the control arm of the PLCO study: Given the high level of contamination in PLCO, one way of interpreting the trial is that it is a study of an active (organized) program of screening versus passive (opportunistic) screening, that is, the current level of screening ongoing in the community a finding of no benefit implies that an organized program does not confer significantly greater mortality benefit for prostate cancer than opportunistic screening as currently carried out in the US. However, the study interpreted in this manner would not be able to answer the question of whether that level of opportunistic screening is conveying a mortality benefit over no screening. Pinsky et al. Clin Trials 2010; 7:303 Pinsky et al. Clin Trials 2010; 7: PLCO: Update ERSPC European Randomized Study of Screening for Prostate Cancer PLCO was not a trial of screening vs. no screening Andriole et al. J Natl Cancer Inst 2012; 104:1 Schröder et al. NEJM 2009; 360:
5 ERSPC ERSPC Population-based study at 7 European centers 182,160 men age randomized (162,387 in core age 55-69) Randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control group that did not receive such screening Some variation in thresholds for biopsy (3.0 ng/ ml vs 4.0 with ancillary tests (DRE/fPSA/TRUS) for values between 2.5 or 3.0 and % compliance with screening in screening arm 86% compliance with biopsy recommendations Incidence 4.8% in control, 8.2% in screening arm 27.8% vs 45.2% of screened vs. control tumors were Gleason 7 Adjusted mortality rate ratio 0.8 ( ) in favor of screening. Mortality rates begin diverging at 7 years (20% reduction in mortality rate) Schröder et al. NEJM 2009; 360:1320 Schröder et al. NEJM 2009; 360: Other findings from ERSPC ERSPC: Adjusting for compliance No substantial heterogeneity among different centers in Europe (mortality reduction varies from 16-26%) Absolute mortality risk reduction 7 per 10,000 men screened NNS: 1,410 NNT: 48 in excess of control group at 9 years NNT to prevent metastasis: 24 Schröder et al. NEJM 2009; 360:1320 Roobol et al. Eur Urol 2009; 56:
6 ERSPC: Update The Göteborg trial 20% risk reduction for cancer-specific mortality with screening (up to 38% in years 10-11) 29% risk reduction with adjustment for noncompliance Men (median 56) in a single Swedish city randomized to biannual screening until age 69 vs. no screening 9952 men in each arm Referral to urologist at PSA 3.4, later reduced to 2.9 then to 2.5 ng/ml. Biopsies used sextant template 76% of men in screening arm were screened at least once; 93% of men with elevated PSA had at least one biopsy Schröder et al. NEJM 2012; 366:981 Hugosson J. Lancet Oncol 2010; 11: The Göteborg randomized trial The Göteborg randomized trial Hugosson J. Lancet Oncol 2010; 11:725 Hugosson J. Lancet Oncol 2010; 11:
7 The Göteborg randomized trial The Göteborg randomized trial biannual PSA testing can lower the risk for prostate cancer-specific mortality by at least 40 percent Göteborg vs. PLCO & ERSPC Younger mean age at start of screening Lower PSA threshold for referral Q2 year interval Higher rate of biopsy among those with high PSA Lower rate of pre- and intra-study PSA contamination Longer follow up (though still relatively short) Hugosson J. Lancet Oncol 2010; 11:725 Hugosson J. Lancet Oncol 2010; 11: From: Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med. 2012;157(2): doi: / Is screening itself harmful? Figure Legend: Relative risk of prostate cancer death for men screened with PSA versus control participants, by country. ERSPC = European Randomized Study of Screening for Prostate Cancer; PLCO = Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Copyright The American College of Physicians. All rights reserved. Heijnsdijk et al. N Engl J Med 367:595,
8 An interesting perspective USPSTF: Assessment of harms What seems to be missing from most of the PSA discussion is that the majority of men will have a normal PSA value and they will be reassured A normal PSA level offers peace of mind, a valued commodity in a world that is frequently full of troubling news. Detsky et al. JAMA 307:1035, 2012 Adequate evidence shows that up to 5 in 1000 men will die within 1 month of prostate cancer surgery and between 10 and 70 men will have serious complications but survive. Radiotherapy and surgery result in long-term adverse effects, including urinary incontinence and erectile dysfunction in at least 200 to 300 of 1000 men treated with these therapies. Radiotherapy is also associated with bowel dysfunction Moyer et al. Ann Intern Med, epub The real problem: overtreatment? Treatment by risk and age Prostate Cancer Risk Assessment Score Cooperberg et al. J Clin Oncol 2010; 28:1117 Bechis et al. J Clin Oncol 2011; 29:
9 Do PCPs care about the USPSTF? Do PCPs care about the USPSTF? Tasian et al. Urol Oncol 30:155, 2012 Prasad et al. JAMA 307:1692, RaGonale for earlier screening (AUA) Establishing a baseline PSA A baseline PSA level above the median for age 40 is a strong predictor of prostate cancer The age adjusted mortality rate for prostate cancer between ages 55 and 64 is significant. Younger men are more likely to have curable cancer PSA is a more specific test for cancer in younger men Earlier and less frequent testing might reduce mortality and costs compared to annual testing beginning later Patients at risk for, but who do not have, cancer may be candidates for chemoprevention PSA at 60 predicts long-term prostate cancer mortality Analysis of 1167 samples from Malmö registry data 11.4% diagnosed, 2.7% died of prostate cancer If PSA <1.0 at age 60, likelihood of prostate cancer death <0.3% 90% of prostate cancer deaths occurred in men with PSA >2.0 (top quartile) Greene et al. J Urol 2009; 182:2232 Vickers et al. BMJ 341,
10 MulGvariable risk assessment PCA3 and Positive Prostate Biopsy Gittelman M, Journal of Urology, Feb Radical Prostatectomy vs. Watchful Waiting Risk Assessment and Risk- Adapted Management Diagnosis Treatment Bill-Axelson et al. New Engl J Med 2011; 364:
11 PIVOT Trial PIVOT Trial Wilt T et al. NEJM 2012; 367:203 Wilt T et al. NEJM 2012; 367: Prostate Cancer Risk Assessment Prostate cancer Current treatment trend in US Goal: informed physician-patient decisions about optimal initial treatment approach and timing
12 So what explains this graph? Treatment Changes Explain Only a Fraction of the Mortality Decline No treatment Treatment Siegel et al. CA Cancer J Clin 2012; 62:10 Cancer, in press. Courtesy of Ruth Etzioni Mortality Trends Suggest a Clear Role for PSA Screening What if we followed the USPSTF recommendation? No treatment Treatment Treatment and screening ERSPC benefit Cancer, in press. Courtesy of Ruth Etzioni
13 D is the wrong conclusion? D is the wrong conclusion? Conclusions Prostate Cancer screening saves lives The USPSTF recommendation downplays benefits D is the wrong conclusion. Guidelines should avoid recommending for or against PSA screening Shared decision making with individual patient Overtreatment is a major public health problem Answers lie in smarter screening, better treatment decisions, not cessation of screening. Future DirecGons: smarter screening, avoid overtreatment, chemopreven7on Focus on populations at highest risk Consider screening earlier (e.g., 40) Screen less frequently if baseline is low (<2.5) Screen for high-risk prostate cancer, don t over-treat low-risk disease Embrace active surveillance Change nomenclature (e.g., PIN and low risk cancer) Continued development of novel biomarkers (PCA3) Consider finasteride chemoprevention
14 Post-test Audience Response 1. I will not offer prostate cancer screening to any men 2. I will only offer prostate cancer screening to men who specifically ask for it 3. I will discuss screening with men with a long life expectancy, and individualize the decision to screen 4. I will screen most men over 40 in good health 5. I am more confused than I was an hour ago. Acknowledgements UCSF Department of Urology Matthew Cooperberg, MD MPH Katsuto Shinohara, MD UCSF Department of Medicine Oanh Nguyen, MD San Francisco Primary Care Focus Group on Prostate Cancer Screening and Treatment
Cancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
More informationThe PLCO Trial Not a comparison of Screening vs no Screening
PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical
More informationProstate cancer. Christopher Eden. The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing.
Prostate cancer Christopher Eden The Royal Surrey County Hospital, Guildford & The Hampshire Clinic, Old Basing. Screening Screening men for PCa (prostate cancer) using PSA (Prostate Specific Antigen blood
More informationPSA Screening and the USPSTF Understanding the Controversy
PSA Screening and the USPSTF Understanding the Controversy Peter C. Albertsen Division of Urology University of Connecticut Farmington, CT, USA USPSTF Final Report 1 Four Key Questions 1. Does PSA based
More informationProstate-Specific Antigen Based Screening: Controversy and Guidelines
Prostate-Specific Antigen Based Screening: Controversy and Guidelines Eric H. Kim and Gerald L. Andriole Institutional Address: Washington University School of Medicine 4960 Children's Place Campus Box
More informationProstate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine
Prostate Cancer Screening: Are We There Yet? March 2010 Andrew M.D. Wolf, MD University of Virginia School of Medicine Case #1 A 55 yo white man with well-controlled hypertension presents for his annual
More informationProstate Cancer. Screening and Diagnosis. Screening. Pardeep Kumar Consultant Urological Surgeon
The Royal Marsden Prostate Cancer Screening and Diagnosis Pardeep Kumar Consultant Urological Surgeon Prostate Cancer Screening and Diagnosis 08 02 2013 2 Screening 1 3 Q1.Lots of men have prostate cancer
More informationProstate Cancer Screening Guideline
Prostate Cancer Screening Guideline Contents Prevention 2 Screening Recommendations 2 Shared Decision Making 2 Test Recommendations 3 Follow-up/Referral 3 Treatment Overview 4 Evidence Summary 4 References
More informationControversites: Screening for Prostate Cancer in Older Adults
Controversites: Screening for Prostate Cancer in Older Adults William Dale, MD, PhD University of Chicago Sections of Geriatrics & Palliative Medicine and Hematology/Oncology Director, Specialized Oncology
More informationTO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER
TO SCREEN OR NOT TO SCREEN: THE PROSTATE CANCER DILEMMA Thomas J Stormont MD January 2012 http://www.youtube.com/watch?v=8jd 7bAHVp0A&feature=related related INTRODUCTION A government health panel (the
More informationUpdate on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward
Update on Prostate Cancer: Screening, Diagnosis, and Treatment Making Sense of the Noise and Directions Forward 33 rd Annual Internal Medicine Update December 5, 2015 Ryan C. Hedgepeth, MD, MS Chief of
More informationCancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationPSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa
PSA screening in asymptomatic men the debate continues www.bpac.org.nz keyword: psa Key messages: PSA is present in the benign and malignant prostate There is currently no national screening programme
More informationModeling Drivers of Cost and Benefit for Policy Development in Cancer
Modeling Drivers of Cost and Benefit for Policy Development in Cancer Harms? Benefits? Costs? Ruth Etzioni Fred Hutchinson Cancer Research Center Seattle, Washington The USPSTF recommends against routine
More informationRole of MRI in the Diagnosis of Prostate Cancer, A Proposal
Clinical and Experimental Medical Sciences, Vol. 1, 2013, no. 3, 111 116 HIKARI Ltd, www.m-hikari.com Role of MRI in the Diagnosis of Prostate Cancer, A Proposal W. Akhter Research Fellow Urology, Bartshealth
More informationPSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
More informationClinical Practice Guidelines and Shared Decision Making for Prostate Cancer Screening
Clinical Practice Guidelines and Shared Decision Making for Prostate Cancer Screening Dr. Roger Luckmann Associate Professor Family Medicine and Community Health UMass Medical School Disclosures I have
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Prostate cancer tests When to use the 4Kscore Test? Screening Prior to 1 st biopsy Prior to negative previous biopsy Prognosis in Gleason 6
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationThomas A. Kollmorgen, M.D. Oregon Urology Institute
Thomas A. Kollmorgen, M.D. Oregon Urology Institute None 240,000 new diagnosis per year, and an estimated 28,100 deaths (2012) 2 nd leading cause of death from cancer in U.S.A. Approximately 1 in 6 men
More informationClinical Practice Guidelines
Clinical Practice Guidelines Prostate Cancer Screening CareMore Quality Management CareMore Health System adopts Clinical Practice Guidelines for the purpose of improving health care and reducing unnecessary
More informationWhat the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation
In the Balance 201207170 M12-0991 open early What the USPSTF Missed in Its Prostate Cancer Screening Recommendation What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening
More informationU.S. Preventive Services Task Force
U.S. Preventive Services Task Force Screening for Prostate Cancer: Recommendation Statement See related Putting Prevention into Practice on page 283. This summary is one in a series excerpted from the
More informationVirtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15.
Virtual Mentor American Medical Association Journal of Ethics January 2011, Volume 13, Number 1: 10-15. CLINICAL CASE The Debate Over Prostate Cancer Screening Guidelines Commentary by Karen E. Hoffman,
More informationThe PSA Controversy: Defining It, Discussing It, and Coping With It
The PSA Controversy: Defining It, Discussing It, and Coping With It 11 TH ANNUAL SYMPOSIUM ON MEN S HEALTH June 12, 2013 The PSA Controversy Defining It, Discussing It and Coping With It As of May 2012,
More informationUpdate on Prostate Cancer Screening Guidelines
www.medscape.com Update on Prostate Cancer Screening Guidelines Christine Gonzalez, PharmD, CHHC US Pharmacist Abstract and Introduction Introduction In the United States, prostate cancer is the most common
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationProstate Cancer Early Detection: Update 2010
Prostate Cancer Early Detection: Update 2010 Prostate Cancer. Disease Burden The most common non-skin cancer, and the second leading cause of cancer death among U.S. men It is estimated that: 1 in 6 men
More informationProstate Cancer Screening: Phantom menace to society. Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System
Prostate Cancer Screening: Phantom menace to society Folusho Ogunfiditimi, DM, MPH, PA-C Vattikuti Urology Institute Henry Ford Health System Objectives USPTF Recommendations on PSA testing Justification
More informationPSA: Prostate Cancer Screening
PSA: Prostate Cancer Screening 42 nd Annual Convention of the Philippines College of Physicians May 7, 2012, SMX Convention Center Jose Albert Cruz Reyes III, MD, FPCS, FPUA, DPBU Institute of Urology
More informationPSA screening: Controversies and Guidelines
PSA screening: Controversies and Guidelines John Phillips, MD, FACS Department of Urology Urology Center of Westchester New York Medical College Historical PerspecGve Cancer of the prostate, although rare,
More informationProstate Cancer Screening Clinical Practice Guideline. Approved by the National Guideline Directors November, 2013
Prostate Cancer Screening Clinical Practice Guideline This guideline is informational only. It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by
More informationPCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationOfficial reprint from UpToDate www.uptodate.com 2013 UpToDate
Official reprint from UpToDate www.uptodate.com 2013 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek
More informationLinköping University Post Print. Randomised prostate cancer screening trial: 20 year follow-up
Linköping University Post Print Randomised prostate cancer screening trial: 20 year follow-up Gabriel Sandblom, Eberhard Varenhorst, Johan Rosell, Owe Lofman and Per Carlsson N.B.: When citing this work,
More informationThe Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development:
The Centers for Medicare & Medicaid Services (CMS) seeks stakeholder comments on the following clinical quality measure under development: Title: Non-Recommended PSA-Based Screening Description: The percentage
More informationDECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING
DECISION AID TOOL PROSTATE CANCER SCREENING WITH PSA TESTING This booklet is what is often called a decision aid. The goals of a decision aid are to help people better understand their medical choices
More informationACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices
Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationProstate cancer is the second most
Treatment Options for Localized Prostate Cancer RAVINDER MOHAN, MD, PhD, and PAUL F. SCHELLHAMMER, MD Eastern Virginia Medical School, Norfolk, Virginia In the United States, more than 90 percent of prostate
More informationPSA Testing for Prostate Cancer An information sheet for men considering a PSA Test
PSA Testing for Prostate Cancer An information sheet for men considering a PSA Test What is the aim of this leaflet? Prostate cancer is a serious condition. The PSA test, which can give an early indication
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences?
EUROPEAN UROLOGY 58 (2010) 46 52 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial ERSPC and PLCO Prostate Cancer Screening Studies: What Are the Differences? Fritz
More informationAdvances in Diagnostic and Molecular Testing in Prostate Cancer
Advances in Diagnostic and Molecular Testing in Prostate Cancer Ashley E. Ross MD PhD Assistant Professor Urology, Oncology, Pathology Johns Hopkins School of Medicine September 24, 2015 1 Disclosures
More informationProstate Cancer Screening. Dr. J. McCracken, Urologist
Prostate Cancer Screening Dr. J. McCracken, Urologist USPSTF Lifetime risk for diagnosis currently estimated at 15.9% Llifetime risk of dying of prostate cancer is 2.8% Seventy percent of deaths due to
More informationScreening for Prostate Cancer
Screening for Prostate Cancer It is now clear that screening for Prostate Cancer discovers the disease at an earlier and more curable stage. It is not yet clear whether this translates into reduced mortality
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationIn 2014, about 233,000 American men. Prostate Cancer Screening
ELIE MULHEM, MD, Oakland University William Beaumont School of Medicine, Sterling Heights, Michigan NIKOLAUS FULBRIGHT, MD, Providence Hospital, South Lyon, Michigan NORAH DUNCAN, MD, Oakland University
More information1. What is the prostate-specific antigen (PSA) test?
1. What is the prostate-specific antigen (PSA) test? Prostate-specific antigen (PSA) is a protein produced by the cells of the prostate gland. The PSA test measures the level of PSA in the blood. The doctor
More informationSRO Tutorial: Prostate Cancer Treatment Options
SRO Tutorial: Prostate Cancer Treatment Options May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible,
More informationScreening for Prostate Cancer With the Prostate-Specific Antigen Test A Review of Current Evidence
Clinical Review & Education Review Screening for Prostate Cancer With the Prostate-Specific Antigen Test A Review of Current Evidence Julia H. Hayes, MD; Michael J. Barry, MD IMPORTANCE Prostate cancer
More informationAn Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection
DOI: 10.1093/jnci/djr028 ARTICLE JNCI djr028 MA JOURNAL NAME Art. No. CE Code The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationPROSTATE CANCER. Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American
PROSTATE CANCER 1. Guidelines for Screening Risk Factors Normal-risk men: No family history of prostate cancer No history of prior screening Not African-American High-risk men: Family history of prostate
More informationFocus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012. Prostate Cancer: Should We Be Screening?
Focus on PSA Screening for Prostate Cancer Vol. 28 Supplement, February 2012 Prostate Cancer: Should We Be Screening? INSIDE THIS ISSUE 2 Why the Controversy? 3 Active Surveillance 4 The Radical Prostatectomy
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationSee also: Web-Only CME quiz
Guidance Statements Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians Amir Qaseem, MD, PhD, MHA; Michael J. Barry, MD; Thomas
More informationAmerican Urological Association (AUA) Guideline
1 (AUA) Guideline EARLY DETECTION OF PROSTATE CANCER: AUA GUIDELINE Approved by the AUA Board of Directors April 2013 Authors disclosure of potential conflicts of interest and author/staff contributions
More informationBY ELECTRONIC SUBMISSION
November 20, 2015 BY ELECTRONIC SUBMISSION Patrick Conway, MD Deputy Administrator for Innovation & Quality Chief Medical Officer Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore,
More informationDraft Clinical Practice Guidelines. PSA Testing and Early Management of Test-Detected Prostate Cancer
Draft Clinical Practice Guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer Draft November 2014 Prostate Cancer Foundation of Australia and Cancer Council Australia ISBN: This
More informationMEDICAL POLICY SUBJECT: PROSTATE CANCER SCREENING, DETECTION AND MONITORING
MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationPROSTATE CANCER SCREENING PROSTATE CANCER SCREENING
3:45 4:45pm Screening Guidelines for Men's Health SPEAKER Radha Rao, MD Presenter Disclosure Information The following relationships exist related to this presentation: Radha Rao, MD: No financial relationships
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationUse Of Testosterone In Men With Prostate Cancer. Traditional view: T is dangerous for PCa
Use Of Testosterone In Men With Prostate Cancer Abraham Morgentaler, MD, FACS Director, Men s s Health Boston Associate Clinical Professor of Urology Harvard Medical School Boston, USA Traditional view:
More informationThe 4Kscore blood test for risk of aggressive prostate cancer
The 4Kscore blood test for risk of aggressive prostate cancer Early detection of aggressive prostate cancer Challenges Serum PSA has a high false positive rate Over 1 million prostate biopsies performed
More informationScreening for Prostate Cancer
Screening for Prostate Cancer Review against programme appraisal criteria for the UK National Screening Committee (UK NSC) Version 1: This document summarises the work of ScHARR 1 2 and places it against
More informationScreening for prostate cancer: the current evidence and guidelines controversy
REVIEW Screening for prostate cancer: the current evidence and guidelines controversy Leonard G. Gomella, MD, 1 Xiaolong S. Liu, MD, 1 Edouard J. Trabulsi, MD, 1 Wm. Kevin Kelly, MD, 2 Ronald Myers, MD,
More informationFocal therapy for prostate cancer: seriously or seriously? Disclosures
Focal therapy for prostate cancer: seriously or seriously? Mitchell Kamrava, MD Assistant Clinical Professor Department of Radiation Oncology University of California Los Angeles Disclosures Speaking honorarium
More informationGuidelines for Cancer Prevention, Early detection & Screening. Prostate Cancer
Guidelines for Cancer Prevention, Early detection & Screening Prostate Cancer Intervention Comments & Recommendations For primary prevention, it has been suggested that diets low in meat & other fatty
More informationPSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men
PSA Test Provides the Early Prostate Cancer Detection That Has Saved the Life of Thousands of Men Table of Contents 1. What the research shows on the effectiveness of the PSA test p. 2 2. PSA test guidelines
More informationEstablishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers
Establishing a Cohort of African-American Men to Validate a Method for using Serial PSA Measures to Detect Aggressive Prostate Cancers James R. Hebert, Sc.D., Cancer Prevention and Control Program, University
More informationThe U.S. Preventive Services Task Force (USPSTF) makes
Annals of Internal Medicine Clinical Guidelines Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement U.S. Preventive Services Task Force* Description: Update of the
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationSIOG Guidelines Update 2014 Prostate Cancer. Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon
SIOG Guidelines Update 2014 Prostate Cancer Dr Helen Boyle Centre Léon Bérard SIOG meeting 25 October 2014,Lisbon Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou
More informationEarly Detection of Prostate Cancer: AUA Guideline
Early Detection of Prostate Cancer: AUA Guideline H. Ballentine Carter, Peter C. Albertsen, Michael J. Barry, Ruth Etzioni, Stephen J. Freedland, Kirsten Lynn Greene, Lars Holmberg, Philip Kantoff, Badrinath
More informationLocal Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153)
Local Coverage Determination (LCD): MolDX: Genomic Health Oncotype DX Prostate Cancer Assay (L36153) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36153
More informationKey Messages for Healthcare Providers
Cancer Care Ontario: Prostate Cancer Screening with the Prostate- Specific Antigen (PSA) Test Key Messages for Healthcare Providers Considerations for men at average risk Avoid prostate-specific antigen
More informationScreening for Prostate Cancer
clinical practice Screening for Prostate Cancer Richard M. Hoffman, M.D., M.P.H. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationProstate Cancer Screening Report and Recommendations
Working together to improve health care quality, outcomes, and affordability in Washington State. Prostate Cancer Screening Report and Recommendations September 2015 Table of Contents Executive Summary...
More informationProstate cancer screening: clinical applications and challenges
Urologic Oncology: Seminars and Original Investigations 22 (2004) 353 357 Seminar article Prostate cancer screening: clinical applications and challenges Otis W. Brawley, M.D.* Winship Cancer Institute,
More informationScreening for Cancer in Light of New Guidelines and Controversies. Christopher Celio, MD St. Jude Heritage Medical Group
Screening for Cancer in Light of New Guidelines and Controversies Christopher Celio, MD St. Jude Heritage Medical Group Screening Tests The 2 major objectives of a good screening program are: (1) detection
More informationJohns Hopkins Hospital
Johns Hopkins Hospital The 12 th Annual Advances in Urology Controversies in Prostate Cancer Patrick C. Walsh, M.D. University Distinguished Service Professor James Buchanan Brady Urological Institute
More informationIntensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study
Annals of Oncology Advance Access published February 22, 2014 1 Intensity-Modulated Radiation Therapy Leads to Survival Benefit Only in Patients with High-Risk Prostate Cancer: a Population-Based Study
More informationProstate cancer volume at biopsy vs. findings at Prostatectomy
Prostate cancer volume at biopsy vs. findings at Prostatectomy May 2005 By Shelly Smits, RHIT, CCS, CTR Ian Thompson, MD Data Source: Cancer registry data of prostate cancer treated with prostatectomy
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationObesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH
Obesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH Professor and Martin D. Abeloff, MD Scholar in Cancer Prevention Department of Epidemiology, Johns Hopkins Bloomberg School
More informationMalpractice Litigation in the Setting of Prostate Cancer Diagnosis
urologypracticejournal.com Malpractice Litigation in the Setting of Prostate Cancer Diagnosis Peter L. Sunaryo,* Marc Colaco, Ronald Davis and Hossein Sadeghi-Nejad From the Division of Urology, Department
More informationProstate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Evidence Synthesis Number 90 Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and
More informationPublished Ahead of Print on July 16, 2012 as 10.1200/JCO.2012.43.3441. J Clin Oncol 30. 2012 by American Society of Clinical Oncology
Published Ahead of Print on July 16, 2012 as 10.1200/JCO.2012.43.3441 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.43.3441 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationFacing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery
Facing Prostate Cancer Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Prostate Cancer Your prostate is a walnut-sized gland that is part of the male reproductive system. The prostate
More informationScreening for Prostate Cancer with Prostate Specific Antigen
Screening for Prostate Cancer with Prostate Specific Antigen January 18, 2013 ERSC Project Lead Investigator: Donna Ciliska ERSC Project Staff: Donna Fitzpatrick-Lewis, Judy Brown, Ali Usman and Maureen
More informationProstate Cancer Screening and the Benefits of Early Diagnosis
Vol.2, No.10, 1179-113 (2010) doi:10.4236/health.2010.210173 Health Prostate cancer screening: a primary care survey Samuel Deem 1 *, Brian DeFade 1, Josh Lohri 1, James P. Tierney 1, Asmita Modak 2, Mary
More informationNovember 25, 2015. Albert L Siu, MD, MSPH Chair, US Preventive Services Task Force 5600 Fishers Lane, Mail Stop 06E53A Rockville, MD 20857
November 25, 2015 Men's Health Network P. O. Box 75972 Washington, D.C. 20013 202-543-MHN-1 (6461) Fax 202-543-2727 Albert L Siu, MD, MSPH Chair, US Preventive Services Task Force 5600 Fishers Lane, Mail
More informationOncology: Prostate/Testis/Penis/Urethra. Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative
Oncology: Prostate/Testis/Penis/Urethra Variation in Prostate Cancer Detection Rates in a Statewide Quality Improvement Collaborative Christopher B. Riedinger, Paul R. Womble, Susan M. Linsell, Zaojun
More information